ClinicalTrials.gg
CompletedNCT00351468EXTENDUpdated Apr 17, 2017Results posted

EXTEND (Eltrombopag Extended Dosing Study)

A Phase 3 interventional study of eltrombopag olamine (SB-497115-GR) in Purpura, Thrombocytopaenic, Idiopathic, sponsored by Novartis Pharmaceuticals. Completed at 110 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-17.

Primary conditionPurpura, Thrombocytopenic, IdiopathicRegistry: PurpuraReclassifiedWhy we changed it
Registry
Purpura — the first condition term the registry derived for this study.
ClinicalTrials.gg
Purpura, Thrombocytopenic, Idiopathic
Why
  1. The study's title name Purpura, Thrombocytopenic, Idiopathic, a narrower term within Purpura.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
302
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
2nd of 36
302 · median 40
Started
2006
with 1 other
Phase 3
9 of 36
none open now
Registered
2nd of 36
by date
Lead sponsor
6 of 36
Novartis Pharmaceuticals

Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 2nd largest by enrollment, is one of 2 that started in 2006, is one of 9 in phase 3, and was the 2nd registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag trial. This study will allow adjustment of the eltrombopag dose to achieve an individualized dose and schedule for each subject. In addition, the ability to reduce the dose of concomitant ITP medications in the presence of eltrombopag, while maintaining platelet counts = 50,000/μL will be investigated.

03

Conditions studied

  • Purpura, Thrombocytopaenic, Idiopathic

Browse trials for

Keywords

  • eltrombopag olamine
  • SB-497115-GR
  • idiopathic thrombocytopenic purpura
  • thrombocytopenia
  • ITP
  • platelets
04

In context

Purpura, Thrombocytopenic, Idiopathic Reclassified

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

This study's enrollment of 302 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Purpura, Thrombocytopenic, Idiopathic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Purpura. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has signed and dated a written .
  • Adults (≥18 years) diagnosed with ITP according to the American Society for Hematology/British Committee for Standards in Haematology (ASH/BCSH) guidelines [George, 1996; BCSH, 2003]. In addition, a peripheral blood smear should support the diagnosis of ITP with no evidence of other disease causative of thrombocytopenia (e.g., pseudo thrombocytopenia, myelofibrosis). The physical examination should not suggest any disease which may cause thrombocytopenia other than ITP.
  • Prior completion of treatment and follow up periods in an ITP study of eltrombopag (e.g., TRA100773 or TRA102537/RAISE or TRA108057/REPEAT).
  • Subjects previously enrolled in Study TRA100773 must have completed the prescribed follow-up ophthalmic assessment at 6 months.
  • Subjects previously enrolled in TRA102537/RAISE or other studies that may lead into EXTEND (e.g., TRA108057/REPEAT) must have completed the treatment and follow-up periods as defined in that protocol.
  • Subject experienced no eltrombopag-related toxicity or other drug intolerance on prior eltrombopag study (e.g., TRA100773 or TRA102537/RAISE or TRA108057/REPEAT) even if resolved; subjects discontinued from previous study due to toxicity will not be eligible unless they received placebo.
  • Subject has no intercurrent medical event, including thrombosis.
  • Subjects must have either initially responded ( count > 100,000/mL) to a previous ITP therapy or have had a bone marrow examination consistent with ITP within 3 years to rule out myelodysplastic syndromes or other causes of thrombocytopenia
  • Previous therapy for ITP with immunoglobulins (IVIg and anti-D) must have been completed at least 1 week prior to first dose of study medication and the platelet count must show a clear downward trend after the last treatment with immunoglobulins. Previous treatment for ITP with splenectomy, rituximab and cyclophosphamide must have been completed at least 4 weeks prior to randomization, or clearly be ineffective.
  • Subjects treated with concomitant ITP medication (e.g. or azathioprine) must be receiving a dose that has been stable for at least 4 weeks prior to randomization. Subjects treated with cyclosporine A, mycophenolate mofetil or danazol must be receiving a dose that has been stable for at least 3 months prior to the first dose of study medication.
  • (PT/INR) and activated partial thromboplastin time (aPTT) must be within 80 to 120% of the normal range with no history of hypercoagulable state.
  • A complete blood count (CBC), within the reference range (including WBC differential not indicative of a disorder other than ITP), with the following exceptions:
  • : Subjects with hemoglobin levels between 10.0 g/dL and the lower limit of normal are eligible for inclusion, if anemia is clearly attributable to ITP (excessive blood loss).
  • ≥1500/mL (1.5 x 10\^9/L) is required for inclusion (elevated WBC/ANC due to steroid treatment is acceptable).
  • The following clinical chemistries MUST NOT exceed the (ULN) reference range by more than 20%: creatinine, , AST, total , and alkaline phosphatase. In addition, total albumin must not be below the lower limit of normal (LLN) by more than 10%.
  • Subject is practicing an acceptable method of (documented in chart). Female subjects (or female partners of male subjects) must either be of non- (hysterectomy, bilateral oophorectomy, bilateral tubal ligation or > 1 year), or of childbearing potential and use one of the following highly effective methods of contraception (i.e., Pearl Index \<1.0%) from two weeks prior to administration of study medication, throughout the study, and 28 days after completion or premature discontinuation from the study:
  • Complete abstinence from intercourse;
  • Intrauterine device (IUD);
  • Two forms of barrier contraception (diaphragm plus spermicide, and for males condom plus spermicide);
  • Male partner is sterile prior to entry into the study and is the only partner of the female;
  • Systemic contraceptives (combined or progesterone only).
  • Subject is able to understand and comply with protocol requirements and instructions.

Exclusion criteria

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  • Any abnormality, other than ITP, identified on the screening examination, or any other medical condition or circumstance, which in the opinion of the investigator makes the subject unsuitable for participation in the study or suggests another diagnosis.
  • Concurrent malignant disease and/or history of cancer treatment with cytotoxic chemotherapy and/or radiotherapy.
  • Any prior history of arterial or venous thrombosis (stroke, , myocardial infarction, deep vein thrombosis or pulmonary embolism), AND≥two of the following risk factors: hormone replacement therapy, systemic (containing estrogen), smoking, diabetes, hypercholesterolemia, medication for hypertension, cancer, hereditary thrombophilic disorders (e.g., Factor V Leiden, ATIII deficiency, etc), or any other family history of arterial or venous thrombosis
  • Pre-existing cardiovascular disease (including congestive heart failure, [NYHA] Grade III/IV), or arrhythmia known to increase the risk of thromboembolic events (e.g. atrial fibrillation), or subjects with a >450 msec.
  • Female subjects who are nursing or pregnant (positive serum or urine b-human chorionic gonadotrophin (b-hCG) pregnancy test) at screening or pre-dose on Day 1.
  • History of alcohol/drug abuse.
  • Treatment with an drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication.
  • Subject treated with drugs that affect function (including but not limited to aspirin, clopidogrel and/or NSAIDs) or anti-coagulants for > 3 consecutive days within 2 weeks of the study start and until the end of the study.
  • History of platelet agglutination abnormality that prevents reliable measurement of platelet counts.
  • All subjects with secondary immune thrombocytopenia, including those with laboratory or clinical evidence of infection, antiphospholipid antibody syndrome, chronic infection, virus infection, or any evidence for active hepatitis at the time of subject screening. If a potential subject has no clinical history that would support HIV infection or hepatitis infection, no further laboratory screening is necessary; however, standard medical practice would suggest further evaluation of patients who have risk factors for these infections.
  • A subject is planning to have cataract surgery.
  • In France, a subject is neither affiliated with nor a beneficiary of a social security category.

Other Eligibility Criteria Considerations:

To assess any potential impact on subject eligibility with regard to safety, the investigator must refer to the following document(s) for detailed information regarding warnings, precautions, , adverse events, and other significant data pertaining to the investigational product(s) being used in this study: CIB, SPM.

Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    Eltrombopag

    Open-label eltrombopag

    Drug: eltrombopag olamine (SB-497115-GR)

Interventions

  • Eltrombopag with starting dose of 50mg daily, max dose of 75mg daily and min dose of 25mg daily or less frequently. Modifications were given to maintain platelet count in range of 50 to 200 Gi/L.

07

What researchers measure

Primary outcomes

  1. Overall Summary of On-Therapy Adverse Events (Safety Population)

    All safety evaluation findings considered to be adverse events are reported in the Adverse Event section.

    Time frame: Start date was the first dose of investigational product and up to the day after the last dose . Post-therapy: start date was more than 1 day after the last dose and up to 30 days after last dose of investigational product up to week 364

Secondary outcomes

  1. Subjects Achieving Maximum Platelet Counts Greater Than or Equal to 30 Gi/L or 50 Gi/L in the Absence of Rescue Medication

    Subjects who achieved maximum platelet count at least once during treatment. All platelet counts after an on-study splenectomy are not classed as responses. Platelet counts within 7 days after a platelet transfusion are not classed as responses. Platelet counts while taking an increased ITP medication or within 6 weeks after the end of an increased ITP medication are not classed as responses.

    Time frame: Baseline up to 2 years

  2. Summary of Subjects Achieving Platelet Count Levels by Week, in the Absence of Rescue Medication

    If a subject has more than 1 platelet count result within a week, the lowest value observed is used to determine response. All platelet counts after an on-study splenectomy are not classed as responses. Platelet counts within 7 days after a platelet transfusion are not classed as responses. Platelet counts while taking an increased ITP medication or within 6 weeks after the end of an increased ITP medication are not classed as responses.

    Time frame: Baseline up to Year 7/Week 364

  3. Number of Subjects Who Responded to Eltrombopag in a Previous Study and Who Respond to Retreatment With a Rise in Platelet Count to Either ≥ 50,000/µL or ≥30,000/µL

    Responder in TRA100773: Platelet count 50 Gi/L and 2 x baseline (BL) at last on-treatment assessment. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline (BL), 50 Gi/L, and 30 Gi/L at any time. Responder in RAISE: Platelet count 50GI/L and 2 x baseline at Week 6 assessment. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline, 50 Gi/L, and 30 Gi/L at any time. Responder in REPEAT: Platelet count 50 GI/L and 2 x baseline (BL) at Week 6 assessment in Cycle 1. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline (BL) 50 Gi/L, and 30 Gi/L at any time.

    Time frame: Baseline up to 2 years

  4. Number of Participants With Reduction and/or Sparing of Concomitant ITP Therapies, While Maintaining a Platelet Count ≥ 50,000/mL.

    Sustain reduct: Sustained reduction 1 Denominator is number of subjects taking an ITP medication at baseline. 2 Denominator is number of subjects with a sustained reduction. Note: Sustained reduction defined as reduction from baseline in dose and/or frequency which is maintained for at least 4 weeks. Excludes sustained reductions started more than 1 day after last dose.

    Time frame: Baseline up to 2 years

  5. Number of Subjects Who Required Rescue Therapy During Treatment With Eltrombopag.

    Rescue treatment is defined as a composite of: new ITP medication, increased dose of a concomitant ITP medication, platelet transfusion, and splenectomy. Subjects may have received more than 1 type of rescue therapy

    Time frame: Baseline up to 2 years

  6. Maximum ITP Bleeding Score at Any Time During the Study During All Stages.

    The ITP bleeding score is a tool which has been designed specifically to assess the bruising and bleeding in patients with ITP across body sites, ranging from mild to severe. The WHO Grades were dichotomized into the following categories: - Grade 0, No bleeding -Grade 1 to 4, Any bleeding -Grade 0 to 1: No clinically significant bleeding -Grade 2 to 4 Clinically significant bleeding

    Time frame: Baseline up to 2 years

  7. Best Post-Baseline Change in SF-36v2 Questionnaire Score From Any Time Point Compared With Baseline

    The SF-36v2 assessment tool was used to obtain information about subjects' general health status and health-related quality of life. Until a formal assessment of minimal clinically important differences (MCID) is performed, changes from baseline of more than 0.5 standard deviations are suggested as clinically meaningful. Scores were transformed to a 0-100 point scale, with higher scores representing more positive answers. Scores were normalized to have a mean of 50 and SD of 10 to allow for comparison with outcomes from other chronic diseases. Recall period is the past week prior to administration. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group

    Time frame: Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years

  8. Best Post-Baseline Change in the Short Form of the Motivation and Energy Scale (MEI-SF) From Any Time Point Compared With Baseline

    The MEI-SF (18 questions) was used to measure the reductions in mental energy, physical energy, and social motivation, either as symptoms of chronic ITP or as a side effect of pharmacotherapy. Minimal clinically important differences are estimated as 0.5 standard deviations or 7.5 points. All items use either a 7-level (0 to 6) or 5-level (0 to 4) response scale; items with a 5-level response scale were rescaled to 7-levels, and items were reverse-scored as necessary such that higher scores represent higher HRQoL Total score ranges from 0 to 108 points. Recall period is past week prior to administration. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group

    Time frame: Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years

  9. Best Post-Baseline Change in the FACIT-Fatigue 13 Item Subscale Score From Any Time Point Compared to Baseline

    The FACIT-Fatigue consists of 13 questions in which patients rate the frequency (0-4) of symptoms of fatigue, in terms of tiredness, weakness, and fatigue Items were reverse-scored as necessary such that higher scores represent higher HRQoL Total score ranges from 0 to 52.Using anchor-based estimates, the minimally important difference in this subscale is 3.0 points. Recall period is past week prior to administration. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group

    Time frame: Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years

  10. Best Post-Baseline Change in the FACT-TH6 at Any Time Point Compared to Baseline

    The FACT-TH6 consists of 6 questions in which patients rate (0-4) their general degree of worry related to bleeding and bruising, and resulting activity impairment and frustration. Although the six items do not constitute a formal domain or subscale of the FACT-Th assessment tool, these items had been identified by focus groups of patients with chronic ITP as important indicators of their HRQoL. Items were reverse-scored as necessary such that higher scores represent higher HRQoL. Total scores ranged from 0 to 24. Recall period is not specified. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group

    Time frame: Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years

08

Results

Posted Apr 17, 2017

Participant flow

Subjects were previously enrolled in a study of eltrombopag: TRA100773A, TRA100773B, TRA102537/RAISE, or TRA108057/REPEAT. Eligibility of consenting subjects was assessed during the screening period of up to 28 days prior to Day 1 of treatment.

Participant flow — Overall Study
MilestoneEltrombopag
Started302
Subjects from tra100773a51
Subjects from tra100773b61
Subjects from tra102537 raise146
Subjects from tra108057 repeat43
Unknown - not from previous trial1
Completed135
Not completed167
Withdrew: Adverse event42
Withdrew: Withdrawal by subject39
Withdrew: Various -follow up w clinical team39
Withdrew: Lack of efficacy32
Withdrew: Non-compliance8
Withdrew: Lost to follow-up4
Withdrew: Protocol violation3

Outcome measures

PrimaryOverall Summary of On-Therapy Adverse Events (Safety Population)

All safety evaluation findings considered to be adverse events are reported in the Adverse Event section.

Time frame:
Start date was the first dose of investigational product and up to the day after the last dose . Post-therapy: start date was more than 1 day after the last dose and up to 30 days after last dose of investigational product up to week 364
Reported as:
Number · Participants
Overall Summary of On-Therapy Adverse Events (Safety Population)
ParticipantsEltrombopag
Any adverse event277
Any serious adverse event96
Adverse events related to study medication133
Adverse events leading to withdrawal41
Serious adverse events leading withdrawal28
SecondarySubjects Achieving Maximum Platelet Counts Greater Than or Equal to 30 Gi/L or 50 Gi/L in the Absence of Rescue Medication

Subjects who achieved maximum platelet count at least once during treatment. All platelet counts after an on-study splenectomy are not classed as responses. Platelet counts within 7 days after a platelet transfusion are not classed as responses. Platelet counts while taking an increased ITP medication or within 6 weeks after the end of an increased ITP medication are not classed as responses.

Time frame:
Baseline up to 2 years
Reported as:
Number · Participants
Subjects Achieving Maximum Platelet Counts Greater Than or Equal to 30 Gi/L or 50 Gi/L in the Absence of Rescue Medication
ParticipantsEltrombopag
Baseline Platelet counts >= 30 Gi/L,91
Baseline Platelet counts >= 50 Gi/L,42
Maximum Platelet Count >= 30 Gi/L276
Maximum Platelet Count >= 50 Gi/L259
SecondarySummary of Subjects Achieving Platelet Count Levels by Week, in the Absence of Rescue Medication

If a subject has more than 1 platelet count result within a week, the lowest value observed is used to determine response. All platelet counts after an on-study splenectomy are not classed as responses. Platelet counts within 7 days after a platelet transfusion are not classed as responses. Platelet counts while taking an increased ITP medication or within 6 weeks after the end of an increased ITP medication are not classed as responses.

Time frame:
Baseline up to Year 7/Week 364
Reported as:
Number · Participants
Summary of Subjects Achieving Platelet Count Levels by Week, in the Absence of Rescue Medication
ParticipantsEltrombopag
Baseline Platelet counts >= 30 Gi/L, n=30291
Baseline Platelet counts >= 50 Gi/L, n=30242
Week 1 Platelet Count >= 30 Gi/L n=293172
Week 1 Platelet Count >= 50 Gi/L n=293127
Week 2 Platelet Count >= 30 Gi/L n=288199
Week 2 Platelet Count >= 50 Gi/L n=288165
Week 3 Platelet Count >= 30 Gi/L n=275192
Week 3 Platelet Count >= 50 Gi/L n=275159
Week 4 Platelet Count >= 30 Gi/L n=275192
Week 4 Platelet Count >= 50 Gi/L n=275149
Week 5 Platelet Count >= 30 Gi/L n=274197
Week 5 Platelet Count >= 50 Gi/L n=274159
Week 6 Platelet Count >= 30 Gi/L n=276203
Week 6 Platelet Count >= 50 Gi/L n=276169
Week 12 Platelet Count >= 30 Gi/L n=197147
Week 12 Platelet Count >= 50 Gi/L n=197120
Month 6/Week 26 Platelet Count >= 30 Gi/L n=13093
Month 6/Week 26 Platelet Count >= 50 Gi/L n=13082
Year 1/Week 52 Platelet Count >= 30 Gi/L n=8362
Year 1/Week 52 Platelet Count >= 50 Gi/L n=8350
Year 1.5/Week 78 Platelet Count >= 30 Gi/L n=6347
Year 1.5/Week78 Platelet Count >= 50 Gi/L n=6341
Year 2/Week 104 Platelet Count >= 30 Gi/L n=5946
Year 2/Week 104 Platelet Count >= 50 Gi/L n=5942
Year 2.5/Week 130 Platelet Count >= 30 Gi/L n=4232
Year 2.5/Week 130 Platelet Count >= 50 Gi/L n=4228
Year 3/Week 156 Platelet Count >= 30 Gi/L n=2722
Year 3/Week 156 Platelet Count >= 50 Gi/L n=2719
Year 3.5/Week 182 Platelet Count >= 30 Gi/L n=2319
Year 3.5/Week 182 Platelet Count >= 50 Gi/L n=2317
Year 4/Week 208 Platelet Count >= 30 Gi/L n=1712
Year 4/Week 208 Platelet Count >= 50 Gi/L n=1711
Year 4.5/Week 234 Platelet Count >= 30 Gi/L n=1513
Year 4.5/Week 234 Platelet Count >= 50 Gi/L n=1512
Year 5/Week 260 Platelet Count >= 30 Gi/L n=96
Year 5/Week 260 Platelet Count >= 50 Gi/L n=96
Year 5.5/Week 286 Platelet Count >= 30 Gi/L n=97
Year 5.5/Week 286 Platelet Count >= 50 Gi/L n=97
Year 6/Week 312 Platelet Count >= 30 Gi/L n=97
Year 6/Week 312 Platelet Count >= 50 Gi/L n=97
Year 6.5/Week 338 Platelet Count >= 30 Gi/L n=53
Year 6.5/Week 338 Platelet Count >= 50 Gi/L n=53
Year 7/Week 364 Platelet Count >= 30 Gi/L n=33
Year 7/Week 364 Platelet Count >= 50 Gi/L n=33
SecondaryNumber of Subjects Who Responded to Eltrombopag in a Previous Study and Who Respond to Retreatment With a Rise in Platelet Count to Either ≥ 50,000/µL or ≥30,000/µL

Responder in TRA100773: Platelet count 50 Gi/L and 2 x baseline (BL) at last on-treatment assessment. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline (BL), 50 Gi/L, and 30 Gi/L at any time. Responder in RAISE: Platelet count 50GI/L and 2 x baseline at Week 6 assessment. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline, 50 Gi/L, and 30 Gi/L at any time. Responder in REPEAT: Platelet count 50 GI/L and 2 x baseline (BL) at Week 6 assessment in Cycle 1. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline (BL) 50 Gi/L, and 30 Gi/L at any time.

Time frame:
Baseline up to 2 years
Reported as:
Number · Participants
Number of Subjects Who Responded to Eltrombopag in a Previous Study and Who Respond to Retreatment With a Rise in Platelet Count to Either ≥ 50,000/µL or ≥30,000/µL
ParticipantsEltrombopag
TRA100773 Responders >= 50 Gi/L in EXTEND, n=5149
TRA100773 >=50 Gi/L and 2 x BL in EXTEND, n=5147
TRA100773 Responders >= 30 Gi/L in EXTEND, n=5149
RAISE Responders >= 50 Gi/L in EXTEND, n=5954
RAISE >= 50 Gi/L and 2 x BL in EXTEND, n=5953
RAISE Responders >= 30 Gi/L in EXTEND, n=5155
REPEAT Responders >= 50 Gi/L in EXTEND, n=3633
REPEAT>= 50 Gi/L and 2 x BL in EXTEND, n=3633
REPEAT Responders >= 30 Gi/L in EXTEND, n=3635
SecondaryNumber of Participants With Reduction and/or Sparing of Concomitant ITP Therapies, While Maintaining a Platelet Count ≥ 50,000/mL.

Sustain reduct: Sustained reduction 1 Denominator is number of subjects taking an ITP medication at baseline. 2 Denominator is number of subjects with a sustained reduction. Note: Sustained reduction defined as reduction from baseline in dose and/or frequency which is maintained for at least 4 weeks. Excludes sustained reductions started more than 1 day after last dose.

Time frame:
Baseline up to 2 years
Reported as:
Number · Participants
Number of Participants With Reduction and/or Sparing of Concomitant ITP Therapies, While Maintaining a Platelet Count ≥ 50,000/mL.
ParticipantsEltrombopag
ITP medication at baseline101
Sustain reduct or stop at least 1 med [1] n=10171
Permanently stopping at least 1 ITP med [1] n=10153
Sustained reduction[1] n=10170
Maximum sustained reduction ≥ 24 weeks[2] n=7066
SecondaryNumber of Subjects Who Required Rescue Therapy During Treatment With Eltrombopag.

Rescue treatment is defined as a composite of: new ITP medication, increased dose of a concomitant ITP medication, platelet transfusion, and splenectomy. Subjects may have received more than 1 type of rescue therapy

Time frame:
Baseline up to 2 years
Reported as:
Number · Participants
Number of Subjects Who Required Rescue Therapy During Treatment With Eltrombopag.
ParticipantsEltrombopag
New ITP medication, n=10382
Increase in dose of ITP med from baseline, n=10327
Platelet transfusion, n=10321
Splenectomy, n=1033
SecondaryMaximum ITP Bleeding Score at Any Time During the Study During All Stages.

The ITP bleeding score is a tool which has been designed specifically to assess the bruising and bleeding in patients with ITP across body sites, ranging from mild to severe. The WHO Grades were dichotomized into the following categories: - Grade 0, No bleeding -Grade 1 to 4, Any bleeding -Grade 0 to 1: No clinically significant bleeding -Grade 2 to 4 Clinically significant bleeding

Time frame:
Baseline up to 2 years
Reported as:
Number · Participants
Maximum ITP Bleeding Score at Any Time During the Study During All Stages.
ParticipantsEltrombopag
Epistaxis n=300 Grade 0204
Epistaxis n=300 Grade 165
Epistaxis n=300 Grade 231
Gastrointestinal n=300 Grade 0264
Gastrointestinal n=300 Grade 126
Gastrointestinal n=300 Grade 210
Genitourinary n=300 Grade 0262
Genitourinary n=300 Grade 129
Genitourinary n=300 Grade 29
Gynecologic n=108 Grade 068
Gynecologic n=108 Grade 115
Gynecologic n=108 Grade 225
Intracerebral hemorrhage n=300 Grade 0297
Intracerebral hemorrhage n=300 Grade 13
Intracerebral hemorrhage n=300 Grade 20
Ocular n=300 Grade 0258
Ocular n=300 Grade 137
Ocular n=300 Grade 25
Oral n=300 Grade 0191
Oral n=300 Grade 181
Oral n=300 Grade 228
Pulmonary n=300 Grade 0287
Pulmonary n=300 Grade 113
Pulmonary n=300 Grade 20
Skin, ecchymosis n=300 Grade 074
Skin, ecchymosis n=300 Grade 1159
Skin, ecchymosis n=300 Grade 267
Skin, petechiae n=300 Grade 0142
Skin, petechiae n=300 Grade 1126
Skin, petechiae n=300 Grade 232
SecondaryBest Post-Baseline Change in SF-36v2 Questionnaire Score From Any Time Point Compared With Baseline

The SF-36v2 assessment tool was used to obtain information about subjects' general health status and health-related quality of life. Until a formal assessment of minimal clinically important differences (MCID) is performed, changes from baseline of more than 0.5 standard deviations are suggested as clinically meaningful. Scores were transformed to a 0-100 point scale, with higher scores representing more positive answers. Scores were normalized to have a mean of 50 and SD of 10 to allow for comparison with outcomes from other chronic diseases. Recall period is the past week prior to administration. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group

Time frame:
Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years
Reported as:
Mean · Points on a scale
Best Post-Baseline Change in SF-36v2 Questionnaire Score From Any Time Point Compared With Baseline
Points on a scaleEltrombopag
SF-36v2 Physical function (n=27312.0 (9.6 to 14.5)
SF-36v2 Physical role (n=273)14.2 (11.5 to 16.9)
SF-36v2 Bodily pain (n=273)14.5 (11.6 to 17.4)
SF-36v2 General health (n=273)11.1 (9.0 to 13.1)
SF-36v2 Vitality (n=290)13.9 (11.6 to 16.3)
SF-36v2 Social function (n=290)12.6 (10.2 to 15.1)
SF-36v2 Emotional role (n=290)11.4 (8.7 to 14.0)
SF-36v2 Mental health (n=290)11.3 (9.4 to 13.3)
SF-36v2 Physical component summary (n=273)5.3 (4.5 to 6.2)
SF-36v2 Mental component summary (n=290)5.8 (4.6 to 6.9)
SecondaryBest Post-Baseline Change in the Short Form of the Motivation and Energy Scale (MEI-SF) From Any Time Point Compared With Baseline

The MEI-SF (18 questions) was used to measure the reductions in mental energy, physical energy, and social motivation, either as symptoms of chronic ITP or as a side effect of pharmacotherapy. Minimal clinically important differences are estimated as 0.5 standard deviations or 7.5 points. All items use either a 7-level (0 to 6) or 5-level (0 to 4) response scale; items with a 5-level response scale were rescaled to 7-levels, and items were reverse-scored as necessary such that higher scores represent higher HRQoL Total score ranges from 0 to 108 points. Recall period is past week prior to administration. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group

Time frame:
Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years
Reported as:
Mean · Points on a scale
Best Post-Baseline Change in the Short Form of the Motivation and Energy Scale (MEI-SF) From Any Time Point Compared With Baseline
Points on a scaleEltrombopag
Best Post-Baseline Change in the Short Form of the Motivation and Energy Scale (MEI-SF) From Any Time Point Compared With Baseline11.3 (9.1 to 13.5)
SecondaryBest Post-Baseline Change in the FACIT-Fatigue 13 Item Subscale Score From Any Time Point Compared to Baseline

The FACIT-Fatigue consists of 13 questions in which patients rate the frequency (0-4) of symptoms of fatigue, in terms of tiredness, weakness, and fatigue Items were reverse-scored as necessary such that higher scores represent higher HRQoL Total score ranges from 0 to 52.Using anchor-based estimates, the minimally important difference in this subscale is 3.0 points. Recall period is past week prior to administration. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group

Time frame:
Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years
Reported as:
Mean · Points on a scale
Best Post-Baseline Change in the FACIT-Fatigue 13 Item Subscale Score From Any Time Point Compared to Baseline
Points on a scaleEltrombopag
Best Post-Baseline Change in the FACIT-Fatigue 13 Item Subscale Score From Any Time Point Compared to Baseline6.9 (5.7 to 8.1)
SecondaryBest Post-Baseline Change in the FACT-TH6 at Any Time Point Compared to Baseline

The FACT-TH6 consists of 6 questions in which patients rate (0-4) their general degree of worry related to bleeding and bruising, and resulting activity impairment and frustration. Although the six items do not constitute a formal domain or subscale of the FACT-Th assessment tool, these items had been identified by focus groups of patients with chronic ITP as important indicators of their HRQoL. Items were reverse-scored as necessary such that higher scores represent higher HRQoL. Total scores ranged from 0 to 24. Recall period is not specified. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group

Time frame:
Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years
Reported as:
Mean · Points on a scale
Best Post-Baseline Change in the FACT-TH6 at Any Time Point Compared to Baseline
Points on a scaleEltrombopag
Best Post-Baseline Change in the FACT-TH6 at Any Time Point Compared to Baseline4.0 (3.4 to 4.6)

Adverse events

Collected over Treatment + 1 Day: start date was between the first dose of investigational product and up to the day after the last dose . Post-therapy: start date was more than 1 day after the last dose and up to 30 days after last dose of investigational product. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag, Treatment + 1 Day—96/302 (31.8%)253/302 (83.8%)
Eltrombopag, >1 to 30 Days Post-Therapy—10/302 (3.3%)28/302 (9.3%)
Most frequent serious events
Showing 10 of 147
Most frequent serious events
EventEltrombopag, Treatment + 1 DayEltrombopag, >1 to 30 Days Post-Therapy
CataractEye disorders16/3020/302
PneumoniaInfections and infestations8/3021/302
AnaemiaBlood and lymphatic system disorders5/3021/302
Alanine aminotransferase increasedInvestigations5/3020/302
Aspartate aminotransferase increasedInvestigations4/3020/302
Blood bilirubin increasedInvestigations4/3020/302
EpistaxisRespiratory, thoracic and mediastinal disorders4/3020/302
Deep vein thrombosisVascular disorders4/3020/302
Urinary tract infectionInfections and infestations3/3020/302
Platelet count decreasedInvestigations3/3020/302
Most frequent other events
Showing 10 of 33
Most frequent other events
EventEltrombopag, Treatment + 1 DayEltrombopag, >1 to 30 Days Post-Therapy
HeadacheNervous system disorders86/3023/302
NasopharyngitisInfections and infestations74/3022/302
Upper respiratory tract infectionInfections and infestations69/3025/302
FatigueGeneral disorders50/3024/302
DiarrhoeaGastrointestinal disorders46/3023/302
ArthralgiaMusculoskeletal and connective tissue disorders45/3020/302
Back painMusculoskeletal and connective tissue disorders39/3020/302
NauseaGastrointestinal disorders34/3021/302
Urinary tract infectionInfections and infestations32/3022/302
CoughRespiratory, thoracic and mediastinal disorders32/3020/302

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Eltrombopag
Mean48.9 ± 15.61
Sex: Female, Male
Sex: Female, Male(Participants)Eltrombopag
Female201
Male101
Concomitant ITP Medication at Baseline
Concomitant ITP Medication at Baseline(Participant)Eltrombopag
Yes101
No201
Splenectomy Status at Baseline
Splenectomy Status at Baseline(Participants)Eltrombopag
Yes115
No187
Baseline Platelet Count
Baseline Platelet Count(Participants)Eltrombopag
<30 Gi/L211
30 - 50 Gi/L52
> 50 Gi/L39
09

Study locations

110 sites
  • Novartis Investigative Site
    Huntsville, Alabama 35805, United States
  • Novartis Investigative Site
    Mobile, Alabama 36608, United States
  • Novartis Investigative Site
    Jonesboro, Arkansas 72401, United States
  • Novartis Investigative Site
    Duarte, California 91010, United States
  • Novartis Investigative Site
    Los Angeles, California 90033, United States
  • Novartis Investigative Site
    San Francisco, California 94143, United States
  • Novartis Investigative Site
    Miami, Florida 33136, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30341, United States
  • Novartis Investigative Site
    Savannah, Georgia 31405, United States
  • Novartis Investigative Site
    Peoria, Illinois 61614, United States
  • Novartis Investigative Site
    New Orleans, Louisiana 70115, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02114, United States
  • Novartis Investigative Site
    Detroit, Michigan 48202, United States
  • Novartis Investigative Site
    Brunsville, Minnesota 55337, United States
  • Novartis Investigative Site
    Albuquerque, New Mexico 87109, United States
  • Novartis Investigative Site
    New York, New York 10021, United States
  • Novartis Investigative Site
    Cleveland, Ohio 44106, United States
  • Novartis Investigative Site
    Portland, Oregon 97227, United States
  • Novartis Investigative Site
    Lubbock, Texas 79410, United States
  • Novartis Investigative Site
    Arlington, Virginia 22205, United States
  • Novartis Investigative Site
    Seattle, Washington 98109, United States
  • Novartis Investigative Site
    Tacoma, Washington 98405, United States
  • Novartis Investigative Site
    Vancouver, Washington 98684, United States
  • Novartis investigative Site
    Garran, Australian Capital Territory 2606, Australia
  • Novartis Investigative Site
    Kogarah, New South Wales 2217, Australia
  • Novartis Investigative Site
    Vienna, A-1090, Austria
  • Novartis Investigative Site
    Hamilton, Ontario L8S 4K1, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2L 4M1, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3T 1E2, Canada
  • Novartis Investigative Site
    Jiang Su Province, 215006, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Tianjin, 300020, China
  • Novartis Investigative Site
    Brno, 625 00, Czech Republic
  • Novartis Investigative Site
    Olomouc, 775 20, Czech Republic
  • Novartis Investigative Site
    Praha 2, 128 20, Czech Republic
  • Novartis Investigative Site
    Odense, 5000, Denmark
  • Novartis Investigative Site
    Kuopio, 70210, Finland
  • Novartis Investigative Site
    Caen cedex 9, 14033, France
  • Novartis Investigative Site
    Créteil, 94010, France
  • Novartis Investigative Site
    Pessac, 33604, France
  • Novartis Investigative Site
    Muenchen, Bayern 80639, Germany
  • Novartis Investigative Site
    Giessen, Hessen 35392, Germany
  • Novartis Investigative Site
    Hannover, Niedersachsen 30159, Germany
  • Novartis Investigative Site
    Hannover, Niedersachsen 30625, Germany
  • Novartis Investigative Site
    Saarbruecken, Saarland 66113, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Athens, 10676, Greece
  • Novartis Investigative Site
    Athens, 11525, Greece
  • Novartis Investigative Site
    Thessaloniki, 57010, Greece
  • Novartis Investigative Site
    Shatin, New Territories, Hong Kong
  • Novartis Investigative Site
    Bologna, Emilia-Romagna 40138, Italy
  • Novartis Investigative Site
    Albano Laziale (Roma), Lazio 00041, Italy
  • Novartis investigative Site
    Milano, Lombardia 20132, Italy
  • Novartis Investigative Site
    Padova, Veneto 35128, Italy
  • Novartis Investigative Site
    Seoul, 136-705, Korea, Republic of
  • Novartis Investigative Site
    Amersfoort, 3816 CP, Netherlands
  • Novartis Investigative Site
    Amsterdam, 1105 AZ, Netherlands
  • Novartis Investigative Site
    Den Haag, 2545 CH, Netherlands
  • Novartis Investigative Site
    Nijmegen, 6525 GA, Netherlands
  • Novartis Investigative Site
    Rotterdam, 3015 GE, Netherlands
  • Novartis Investigative Site
    Auckland, 2024, New Zealand
  • Novartis Investigative Site
    Christchurch, 8011, New Zealand
  • Novartis Investigative Site
    Grafton, 1001, New Zealand
  • Novartis Investigative Site
    Takapuna, Auckland, 0622, New Zealand
  • Novartis Investigative Site
    Karachi, 75300, Pakistan
  • Novartis Investigative Site
    Lahore, 54600, Pakistan
  • Novartis Investigative Site
    Lima, Lima 27, Peru
  • Novartis Investigative Site
    Lima, Lima 41, Peru
  • Novartis Investigative Site
    Bialystok, 15-276, Poland
  • Novartis Investigative Site
    Lodz, 93-510, Poland
  • Novartis Investigative Site
    Lublin, 20-081, Poland
  • Novartis Investigative Site
    Slupsk, 76-200, Poland
  • Novartis Investigative Site
    Torun, 87-100, Poland
  • Novartis Investigative Site
    Wroclaw, 50-367, Poland
  • Novartis Investigative Site
    Bucharest, 022328, Romania
  • Novartis Investigative Site
    Bucharest, 050098, Romania
  • Novartis Investigative Site
    Moscow, 105 229, Russian Federation
  • Novartis Investigative Site
    Moscow, 125167, Russian Federation
  • Novartis Investigative Site
    Novosibirsk, 630087, Russian Federation
  • Novartis investigative Site
    St Petersburg, 193024, Russian Federation
  • Novartis Investigative Site
    Kosice, 041 90, Slovakia
  • Novartis Investigative Site
    Presov, 080 01, Slovakia
  • Novartis Investigative Site
    Ljubljana, 1000, Slovenia
  • Novartis Investigative Site
    Badalona/Barcelona, 08916, Spain
  • Novartis Investigative Site
    Barcelona, 08025, Spain
  • Novartis Investigative Site
    Madrid, 28006, Spain
  • Novartis Investigative Site
    Madrid, 28007, Spain
  • Novartis Investigative Site
    Palma de Mallorca, 07014, Spain
  • Novartis Investigative Site
    Pamplona, 31008, Spain
  • Novartis Investigative Site
    Santiago de Compostela, 15706, Spain
  • Novartis Investigative Site
    Göteborg, SE-413 45, Sweden
  • Novartis Investigative Site
    Stockholm, SE 171 76, Sweden
  • Novartis Investigative Site
    Taipei, 100, Taiwan
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Khon Kaen, 40002, Thailand
  • Novartis investigative Site
    Montfleury, 1008, Tunisia
  • Novartis investigative Site
    Sfax, 3029, Tunisia
  • Novartis Investigative Site
    Sousse, 4000, Tunisia
  • Novartis Investigative Site
    Tunis, 1008, Tunisia
  • Novartis Investigative Site
    Dnipropetrovsk, 49102, Ukraine

Showing the first 100 of 110 sites across 31 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017 Dec 7;130(23):2527-2536. doi: 10.1182/blood-2017-04-748707. Epub 2017 Oct 17. Erratum In: Blood. 2018 Feb 8;131(6):709. doi: 10.1182/blood-2017-12-823252. PubMed 29042367 ↗
  • Tarantino MD, Fogarty P, Mayer B, Vasey SY, Brainsky A. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul Fibrinolysis. 2013 Apr;24(3):284-96. doi: 10.1097/MBC.0b013e32835fac99. PubMed 23492914 ↗
  • Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013 Jan 17;121(3):537-45. doi: 10.1182/blood-2012-04-425512. Epub 2012 Nov 20. PubMed 23169778 ↗
  • Fogarty PF, Tarantino MD, Brainsky A, Signorovitch J, Grotzinger KM. Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012 Jan;28(1):79-87. doi: 10.1185/03007995.2011.644849. Epub 2011 Dec 20. PubMed 22117897 ↗
  • Signorovitch J, Brainsky A, Grotzinger KM. Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia. Qual Life Res. 2011 Dec;20(10):1737-44. doi: 10.1007/s11136-011-9912-9. Epub 2011 May 1. PubMed 21533818 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2006
First posted
Jul 12, 2006
Start
Jun 2006
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results first posted
Apr 17, 2017
Last update
Apr 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00351468
Responsible party
Sponsor
First posted
Jul 12, 2006
Start date
Jun 2006
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Apr 17, 2017
Last update
Apr 17, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion